|
1
|
Wilson TA, Karajannis MA and Harter DH:
Glioblastoma multiforme: state of the art and future therapeutics.
Surg Neurol Int. 5:642014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hande KR: Clinical applications of
anticancer drugs targeted to topoisomerase II. Biochim Biophys
Acta. 1400:173–184. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swift LP, Rephaeli A, Nudelman A, Phillips
DR and Cutts SM: Doxorubicin-DNA adducts induce a non-topoisomerase
II-mediated form of cell death. Cancer Res. 66:4863–4871. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanafy FM, Salem T, El-Aziz A, EL-Fiky B
and Shokair M: Influence of anticancer drugs on DNA methylation in
liver of female mice. Am J Mol Biol. 1:62–69. 2011. View Article : Google Scholar
|
|
5
|
Yu J, Zhang H, Gu J, et al: Methylation
profiles of thirty four promoter-CpG islands and concordant
methylation behaviours of sixteen genes that may contribute to
carcinogenesis of astrocytoma. BMC Cancer. 4:652004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Horiguchi K, Tomizawa Y, Tosaka M, et al:
Epigenetic inactivation of RASSF1A candidate tumor suppressor gene
at 3p21.3 in brain tumors. Oncogene. 22:7862–7865. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wiencke JK, Zheng S, Jelluma N, et al:
Methylation of the PTEN promoter defines low-grade gliomas and
secondary glioblastoma. Neuro Oncol. 9:271–279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cankovic M, Mikkelsen T, Rosenblum ML and
Zarbo RJ: A simplified laboratory validated assay for MGMT promoter
hypermethylation analysis of glioma specimens from formalin-fixed
paraffin-embedded tissue. Lab Invest. 87:392–397. 2007.PubMed/NCBI
|
|
9
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vijayaraghavalu S and Labhasetwar V:
Efficacy of decitabine-loaded nanogels in overcoming cancer drug
resistance is mediated via sustained DNA methyltransferase 1
(DNMT1) depletion. Cancer Lett. 331:122–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robert MF, Morin S, Beaulieu N, et al:
DNMT1 is required to maintain CpG methylation and aberrant gene
silencing in human cancer cells. Nat Genet. 33:61–65. 2003.
View Article : Google Scholar
|
|
12
|
Zhou W, Chen H, Hong X, Niu X and Lu Q:
Knockdown of DNA methyltransferase-1 inhibits proliferation and
derepresses tumor suppressor genes in myeloma cells. Oncol Lett.
8:2130–2134. 2014.PubMed/NCBI
|
|
13
|
Yokochi T and Robertson KD: Doxorubicin
inhibits DNMT1, resulting in conditional apoptosis. Mol Pharmacol.
66:1415–1420. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar :
|
|
15
|
Gaur AB, Holbeck SL, Colburn NH and Israel
MA: Downregulation of Pdcd4 by mir-21 facilitates glioblastoma
proliferation in vivo. Neuro Oncol. 13:580–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ziyan W, Shuhua Y, Xiufang W and Xiaoyun
L: MicroRNA-21 is involved in osteosarcoma cell invasion and
migration. Med Oncol. 28:1469–1474. 2011. View Article : Google Scholar
|
|
17
|
Kim N, Kim H, Jung I, Kim Y, Kim D and Han
YM: Expression profiles of miRNAs in human embryonic stem cells
during hepatocyte differentiation. Hepatol Res. 41:170–183. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gabriely G, Wurdinger T, Kesari S, et al:
MicroRNA 21 promotes glioma invasion by targeting matrix
metalloproteinase regulators. Mol Cell Biol. 28:5369–5380. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qiu LY and Bae YH: Self-assembled
polyethylenimine-graft-polyb(epsilon-caprolactone) micelles as
potential dual carriers of genes and anticancer drugs.
Biomaterials. 28:4132–4142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng D, Cao N, Chen J, Yu X and Shuai X:
Multifunctional nanocarrier mediated co-delivery of doxorubicin and
siRNA for synergistic enhancement of glioma apoptosis in rat.
Biomaterials. 33:1170–1179. 2012. View Article : Google Scholar
|
|
22
|
Jin W, Wu L, Liang K, Liu B, Lu Y and Fan
Z: Roles of the PI-3K and MEK pathways in Ras-mediated
chemoresistance in breast cancer cells. Br J Cancer. 89:185–191.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li B, Li J, Xu WW, et al: Suppression of
esophageal tumor growth and chemoresistance by directly targeting
the PI3K/AKT pathway. Oncotarget. 5:11576–11587. 2014.PubMed/NCBI
|
|
24
|
Oki E, Baba H, Tokunaga E, et al: Akt
phosphorylation associates with LOH of PTEN and leads to
chemoresistance for gastric cancer. Int J Cancer. 117:376–380.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Choe G, Horvath S, Cloughesy TF, et al:
Analysis of the phosphatidylinositol 3′-kinase signaling pathway in
glioblastoma patients in vivo. Cancer Res. 63:2742–2746.
2003.PubMed/NCBI
|
|
26
|
Huang PH, Mukasa A, Bonavia R, et al:
Quantitative analysis of EGFRvIII cellular signaling networks
reveals a combinatorial therapeutic strategy for glioblastoma. Proc
Natl Acad Sci USA. 104:12867–12872. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martinez R and Esteller M: The DNA
methylome of glioblastoma multiforme. Neurobiol Dis. 39:40–46.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Davalos V, Moutinho C, Villanueva A, et
al: Dynamic epigenetic regulation of the microRNA-200 family
mediates epithelial and mesenchymal transitions in human
tumorigenesis. Oncogene. 31:2062–2074. 2012. View Article : Google Scholar :
|
|
29
|
Wang XF, Shi ZM, Wang XR, et al: MiR-181d
acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2.
J Cancer Res Clin Oncol. 138:573–584. 2012. View Article : Google Scholar
|
|
30
|
Shi ZD, Qian XM, Zhang JX, et al: BASI, a
potent small molecular inhibitor, inhibits glioblastoma progression
by targeting microRNA-mediated beta-catenin signaling. CNS Neurosci
Ther. 20:830–839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cong N, Du P, Zhang A, et al:
Downregulated microRNA-200a promotes EMT and tumor growth through
the wnt/beta-catenin pathway by targeting the E-cadherin repressors
ZEB1/ZEB2 in gastric adenocarcinoma. Oncol Rep. 29:1579–1587.
2013.PubMed/NCBI
|
|
33
|
Su J, Zhang A, Shi Z, et al: MicroRNA-200a
suppresses the Wnt/beta-catenin signaling pathway by interacting
with beta-catenin. Int J Oncol. 40:1162–1170. 2012.PubMed/NCBI
|
|
34
|
Kulis M and Esteller M: DNA methylation
and cancer. Adv Genet. 70:27–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baylin SB and Herman JG: DNA
hypermethylation in tumorigenesis: epigenetics joins genetics.
Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kato K, Long NK, Makita H, et al: Effects
of green tea poly-phenol on methylation status of RECK gene and
cancer cell invasion in oral squamous cell carcinoma cells. Br J
Cancer. 99:647–654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lopez-Serra P and Esteller M: DNA
methylation-associated silencing of tumor-suppressor microRNAs in
cancer. Oncogene. 31:1609–1622. 2012. View Article : Google Scholar :
|
|
38
|
Alakhova DY, Zhao Y, Li S and Kabanov AV:
Effect of doxorubicin/pluronic SP1049C on tumorigenicity,
aggressiveness, DNA methylation and stem cell markers in murine
leukemia. PLoS One. 8:e722382013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mutze K, Langer R, Schumacher F, et al:
DNA methyltransferase 1 as a predictive biomarker and potential
therapeutic target for chemotherapy in gastric cancer. Eur J
Cancer. 47:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Clements EG, Mohammad HP, Leadem BR, et
al: DNMT1 modulates gene expression without its catalytic activity
partially through its interactions with histone-modifying enzymes.
Nucleic Acids Res. 40:4334–4346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nasonkin IO, Merbs SL, Lazo K, et al:
Conditional knockdown of DNA methyltransferase 1 reveals a key role
of retinal pigment epithelium integrity in photoreceptor outer
segment morphogenesis. Development. 140:1330–1341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu M, Gao J, Du YQ, et al: Reduction of
pancreatic cancer cell viability and induction of apoptosis
mediated by siRNA targeting DNMT1 through suppression of total DNA
methyltransferase activity. Mol Med Rep. 3:699–704. 2010.
|
|
43
|
Kundakovic M, Chen Y, Costa E and Grayson
DR: DNA methyltransferase inhibitors coordinately induce expression
of the human reelin and glutamic acid decarboxylase 67 genes. Mol
Pharmacol. 71:644–653. 2007. View Article : Google Scholar
|
|
44
|
Mortusewicz O, Schermelleh L, Walter J,
Cardoso MC and Leonhardt H: Recruitment of DNA methyltransferase I
to DNA repair sites. Proc Natl Acad Sci USA. 102:8905–8909. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rajendran G, Shanmuganandam K, Bendre A,
Muzumdar D, Goel A and Shiras A: Epigenetic regulation of DNA
methyltransferases: DNMT1 and DNMT3B in gliomas. J Neurooncol.
104:483–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lujambio A, Ropero S, Ballestar E, et al:
Genetic unmasking of an epigenetically silenced microRNA in human
cancer cells. Cancer Res. 67:1424–1429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bader AG, Brown D and Winkler M: The
promise of microRNA replacement therapy. Cancer Res. 70:7027–7030.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao W, Shen H, Liu L, Xu J, Xu J and Shu
Y: MiR-21 over-expression in human primary squamous cell lung
carcinoma is associated with poor patient prognosis. J Cancer Res
Clin Oncol. 137:557–566. 2011. View Article : Google Scholar
|
|
49
|
Lakomy R, Sana J, Hankeova S, et al:
MiR-195, miR-196b, miR-181c,
miR-21expressionlevelsandO-6-methylguanine-DNA methyltransferase
methylation status are associated with clinical outcome in
glioblastoma patients. Cancer Sci. 102:2186–2190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shi Z, Zhang J, Qian X, et al: AC1MMYR2,
an inhibitor of dicer-mediated biogenesis of Oncomir miR-21,
reverses epithelial-mesenchymal transition and suppresses tumor
growth and progression. Cancer Res. 73:5519–5531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Han L, Yue X, Zhou X, et al: MicroRNA-21
expression is regulated by beta-catenin/STAT3 pathway and promotes
glioma cell invasion by direct targeting RECK. CNS Neurosci Ther.
18:573–583. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang KL, Han L, Chen LY, et al: Blockage
of a miR-21/EGFR regulatory feedback loop augments anti-EGFR
therapy in glioblastomas. Cancer Lett. 342:139–149. 2014.
View Article : Google Scholar
|
|
53
|
Ren Y, Zhou X, Mei M, et al: MicroRNA-21
inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant)
and LN229 (PTEN-wild type) to taxol. BMC Cancer. 10:272010.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ren Y, Kang CS, Yuan XB, et al:
Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer
attenuates human glioma cell growth in vitro. J Biomater Sci Polym
Ed. 21:303–314. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qian X, Ren Y, Shi Z, et al:
Sequence-dependent synergistic inhibition of human glioma cell
lines by combined temozolomide and miR-21 inhibitor gene therapy.
Mol Pharm. 9:2636–2645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zavadil J, Narasimhan M, Blumenberg M and
Schneider RJ: Transforming growth factor-beta and microRNA: mRNA
regulatory networks in epithelial plasticity. Cells Tissues Organs.
185:157–161. 2007. View Article : Google Scholar
|
|
58
|
Han L, Yang Y, Yue X, et al: Inactivation
of PI3K/AKT signaling inhibits glioma cell growth through
modulation of beta-catenin-mediated transcription. Brain Res.
1366:9–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
